FDA staff questions Lilly drug for Alzheimer’s test

Tuesday, January 18th, 2011

U.S. health reviewers’ main concern with Eli Lilly & Co’s imaging agent for Alzheimer’s tests is whether technicians can properly read the scans and how useful they are in assessing the degenerative disease.

Read more:
FDA staff questions Lilly drug ... continue reading